Skip to main content
Fig. 2 | Allergy, Asthma & Clinical Immunology

Fig. 2

From: Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom

Fig. 2

Proportion of the UK and non-UK IOS patients with days of missed work or education prior to IOS entry and during the IOS observation period. For the UK and non-UK patients, respectively, n = 49 and n = 125 for the period before IOS entry and n = 51 and n = 201 for the IOS follow-up period. BL baseline (12 months prior to IOS entry), FU follow-up, IOS Icatibant Outcome Survey. aNon-UK countries are Austria, Brazil, Denmark, France, Germany, Greece, Israel, Italy, Spain and Sweden

Back to article page